Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT101 in Metastatic or Recurrent Solid Tumors
NCT05430373Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- May 2022
- Primary completion
- Sep 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor infiltrating lymphocytes GT101 in solid tumor, sponsored by Grit Biotechnology. Primary endpoints: Safety Profile Measured by Grade >=3 Treatment-Emergent Adverse Events at 3 years, Objective Response Rate at 3 years and 4 more. Started May 2022; status: recruiting.
02
Drugs
autologous tumor infiltrating lymphocytes GT101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05430373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430373.